Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.
Saved in:
| Title: | Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. |
|---|---|
| Authors: | Narayan VM; Department of Urology, Emory University School of Medicine, Atlanta, Georgia., Boorjian SA; Department of Urology, Mayo Clinic, Rochester, Minnesota., Alemozaffar M; Department of Urology, Southern California Permanente Medical Group, Los Angeles, California., Konety BR; Department of Urology, University of Minnesota and Allina Health Cancer Institute, Minneapolis, Minnesota., Shore ND; Carolina Urologic Research Center, Myrtle Beach, South Carolina., Gomella LG; Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania., Kamat AM; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas., Bivalacqua TJ; Division of Urology, Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania., Montgomery JS; Department of Urology, University of Michigan, Ann Arbor, Michigan., Lerner SP; Scott Department of Urology, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas., Busby JE; Cancer Centers of the Carolinas, Greenville Hospital System, Greenville, South Carolina., Poch M; Department of GU Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida., Crispen PL; Department of Urology, University of Florida, Gainesville, Florida., Steinberg GD; Department of Urology, Rush University, Chicago, Illinois., Schuckman AK; USC Institute of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California., Downs TM; Department of Urology, University of Virginia, Charlottesville, Virginia., Mashni J Jr; Banner MD Anderson Cancer Center, Gilbert, Arizona., Lane BR; Division of Urology, Spectrum Health, Michigan State University College of Human Medicine, Grand Rapids, Michigan., Guzzo TJ; Division of Urology, Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania., Bratslavsky G; Department of Urology, SUNY Upstate Medical University, Syracuse, New York., Karsh LI; The Urology Center of Colorado, Denver, Colorado., Woods ME; Department of Urology, Loyola University Medical Center, Maywood, Illinois., Brown G; New Jersey Urology, Bloomfield, New Jersey., Canter D; Georgia Urology, Atlanta, Georgia., Luchey A; West Virginia University Cancer Institute, Morgantown, West Virginia., Lotan Y; Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas., Inman BA; Division of Urology, Department of Surgery, Western University, London, Ontario, Canada., Williams MB; Urology of Virginia, Virginia Beach, Virginia., Cookson MS; Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma., Chang SS; Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee., Sankin AI; Department of Urology, Montefiore Medical Center, Bronx, New York., O'Donnell MA; Department of Urology, University of Iowa, Iowa City, Iowa., Sawutz D; FKD Therapies Oy, Kuopio, Finland., Philipson R; Calliditas Therapeutics, Stockholm, Sweden., Parker NR; AI Virtanen Institute University of Eastern Finland and Science Service Center and Gene Therapy Unit, Kuopio, Finland., Yla-Herttuala S; AI Virtanen Institute University of Eastern Finland and Science Service Center and Gene Therapy Unit, Kuopio, Finland., Rehm D; Ferring Pharmaceuticals A/S, Copenhagen, Denmark., Jakobsen JS; Ferring Pharmaceuticals A/S, Copenhagen, Denmark., Juul K; Ferring Pharmaceuticals A/S, Copenhagen, Denmark., Dinney CPN; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, Texas. |
| Source: | The Journal of urology [J Urol] 2024 Jul; Vol. 212 (1), pp. 74-86. Date of Electronic Publication: 2024 May 05. |
| Publication Type: | Journal Article; Clinical Trial, Phase III; Multicenter Study |
| Journal Info: | Publisher: Wolters Kluwer Country of Publication: United States NLM ID: 0376374 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-3792 (Electronic) Linking ISSN: 00225347 NLM ISO Abbreviation: J Urol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
